These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 38349726)

  • 61. Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients with MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis.
    Noureddin M; Charlton MR; Harrison SA; Bansal MB; Alkhouri N; Loomba R; Sanyal AJ; Rinella ME
    Clin Gastroenterol Hepatol; 2024 Jul; ():. PubMed ID: 39038768
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma.
    Ha S; Wong VW; Zhang X; Yu J
    Gut; 2024 Jun; ():. PubMed ID: 38950910
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Metabolic dysfunction-associated steatotic liver disease has become the most common cause of hepatocellular carcinoma in Sweden: A nationwide cohort study.
    Vaz J; Jepsen P; Strömberg U; Midlöv P; Eriksson B; Buchebner D; Hagström H
    Int J Cancer; 2024 Jul; ():. PubMed ID: 39016032
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma.
    Rivera-Esteban J; Muñoz-Martínez S; Higuera M; Sena E; Bermúdez-Ramos M; Bañares J; Martínez-Gomez M; Cusidó MS; Jiménez-Masip A; Francque SM; Tacke F; Minguez B; Pericàs JM
    Clin Gastroenterol Hepatol; 2024 Sep; 22(9):1774-1789.e8. PubMed ID: 38604295
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH.
    Anstee QM; Magnanensi J; Hajji Y; Caron A; Majd Z; Rosenquist C; Hum DW; Staels B; Connelly MA; Loomba R; Harrison SA; Ratziu V; Sanyal AJ
    JHEP Rep; 2024 Apr; 6(4):101011. PubMed ID: 38463540
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Transcriptomics-driven metabolic pathway analysis reveals similar alterations in lipid metabolism in mouse MASH model and human.
    Tsouka S; Kumar P; Seubnooch P; Freiburghaus K; St-Pierre M; Dufour JF; Masoodi M
    Commun Med (Lond); 2024 Mar; 4(1):39. PubMed ID: 38443644
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dynamic changes of gut microbiota in mouse models of metabolic dysfunction-associated steatohepatitis and its transition to hepatocellular carcinoma.
    Wang YL; Liu C; Yang YY; Zhang L; Guo X; Niu C; Zhang NP; Ding J; Wu J
    FASEB J; 2024 Jul; 38(13):e23766. PubMed ID: 38967214
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Interleukin-21 receptor signaling promotes metabolic dysfunction-associated steatohepatitis-driven hepatocellular carcinoma by inducing immunosuppressive IgA
    Xie Y; Huang Y; Li ZY; Jiang W; Shi NX; Lu Y; Cao G; Yin Z; Lin XJ
    Mol Cancer; 2024 May; 23(1):95. PubMed ID: 38720319
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Natural history of metabolic dysfunction-associated steatotic liver disease.
    Lekakis V; Papatheodoridis GV
    Eur J Intern Med; 2024 Apr; 122():3-10. PubMed ID: 37940495
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The "Domino effect" in MASLD: The inflammatory cascade of steatohepatitis.
    Mladenić K; Lenartić M; Marinović S; Polić B; Wensveen FM
    Eur J Immunol; 2024 Apr; 54(4):e2149641. PubMed ID: 38314819
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin.
    Meroni M; Longo M; Dongiovanni P
    Front Endocrinol (Lausanne); 2024; 15():1411706. PubMed ID: 38846491
    [TBL] [Abstract][Full Text] [Related]  

  • 72. GDF15: Immunomodulatory Role in Hepatocellular Carcinoma Pathogenesis and Therapeutic Implications.
    Du YN; Zhao JW
    J Hepatocell Carcinoma; 2024; 11():1171-1183. PubMed ID: 38911292
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease.
    Ni K; Meng L
    Clin Res Hepatol Gastroenterol; 2024 Aug; 48(7):102381. PubMed ID: 38821484
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Can liquid biopsies for MASH help increase the penetration of metabolic surgery? A narrative review.
    Castagneto-Gissey L; Bornstein SR; Mingrone G
    Metabolism; 2024 Feb; 151():155721. PubMed ID: 37923007
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The potential role of omentin-1 in obesity-related metabolic dysfunction-associated steatotic liver disease: evidence from translational studies.
    Salvoza N; Giraudi P; Gazzin S; Bonazza D; Palmisano S; de Manzini N; Zanconati F; Raseni A; Sirianni F; Tiribelli C; Rosso N
    J Transl Med; 2023 Dec; 21(1):906. PubMed ID: 38082368
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Disparities for Hispanic Adults With Metabolic Dysfunction-associated Steatotic Liver Disease in the United States: A Systematic Review and Meta-analysis.
    Tesfai K; Pace J; El-Newihi N; Martinez ME; Tincopa M; Loomba R
    Clin Gastroenterol Hepatol; 2024 Jul; ():. PubMed ID: 39025254
    [TBL] [Abstract][Full Text] [Related]  

  • 77. New and emerging treatments for metabolic dysfunction-associated steatohepatitis.
    Tincopa MA; Anstee QM; Loomba R
    Cell Metab; 2024 May; 36(5):912-926. PubMed ID: 38608696
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Hepatic glucose metabolism in the steatotic liver.
    Scoditti E; Sabatini S; Carli F; Gastaldelli A
    Nat Rev Gastroenterol Hepatol; 2024 May; 21(5):319-334. PubMed ID: 38308003
    [TBL] [Abstract][Full Text] [Related]  

  • 79. NIS2+
    Ratziu V; Harrison SA; Hajji Y; Magnanensi J; Petit S; Majd Z; Delecroix E; Rosenquist C; Hum D; Staels B; Anstee QM; Sanyal AJ
    J Hepatol; 2024 Feb; 80(2):209-219. PubMed ID: 38061448
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Emerging role of ferroptosis in metabolic dysfunction-associated steatotic liver disease: revisiting hepatic lipid peroxidation.
    Peleman C; Francque S; Berghe TV
    EBioMedicine; 2024 Apr; 102():105088. PubMed ID: 38537604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.